{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T15:32:41Z","timestamp":1779118361070,"version":"3.51.4"},"reference-count":56,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,1,30]],"date-time":"2015-01-30T00:00:00Z","timestamp":1422576000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["journal-of-hepatology.eu","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1016\/j.jhep.2015.01.028","type":"journal-article","created":{"date-parts":[[2015,1,31]],"date-time":"2015-01-31T09:42:57Z","timestamp":1422697377000},"page":"1196-1203","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Clinical trial watch: Reports from the AASLD Liver Meeting\u00ae, Boston, November 2014"],"prefix":"10.1016","volume":"62","author":[{"given":"Mar\u00eda-Carlota","family":"Londo\u00f1o","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan G.","family":"Abraldes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9","family":"Altamirano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Decaens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xavier","family":"Forns","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2015.01.028_b0005","first-page":"220A","article-title":"Evaluation of sofosbuvir and simeprevir-based regimens in the TRIO network: academic and community treatment of a real-world, heterogeneous population","volume":"60","author":"Dieterich","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.01.028_b0010","first-page":"219A","article-title":"Safety and efficacy of sofosbuvir-containing regimens for hepatitis C: real-world experience in a diverse, longitudinal observational cohort","volume":"60","author":"Jenssen","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.01.028_b0015","first-page":"1270A","article-title":"Ledipasvir\/sofosbuvir fixed dose combination is safe and efficacious in cirrhotic patients who have previously failed protease-inhibitor based triple therapy","volume":"60","author":"Bourliere","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.01.028_b0020","first-page":"317A","article-title":"Retreatment of patients who failed prior sofosbuvir-based regimens with all oral fixed-dose combination ledipasvir\/sofosbuvir plus ribavirin for 12weeks","volume":"60","author":"Wyles","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.01.028_b0025","first-page":"1268A","article-title":"All-oral 12-week combination treatment with Daclatasvir and sofosbuvir in patients infected with HCV genotype 3: ALLY-3 phase 3 study","volume":"60","author":"Nelson","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.01.028_b0030","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJMoa1316145","article-title":"Sofosbuvir and ribavirin in HCV genotypes 2 and 3","volume":"370","author":"Zeuzem","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2015.01.028_b0035","first-page":"239A","article-title":"An integrated safety and efficacy analysis of >500 patients with compensated cirrhosis treated with ledipasvir\/sofosbuvir with or without ribavirin","volume":"60","author":"Bourliere","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.01.028_b0040","first-page":"320A","article-title":"Ledipasvir\/sofosbuvir with ribavirin for the treatment of HCV in patients with decompensated cirrhosis: preliminary results of a prospective, multicenter study","volume":"60","author":"Flamm","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.01.028_b0045","first-page":"200A","article-title":"Ledipasvir\/sofosbuvir with ribavirin for the treatment of HCD in patients with post-transplant recurrence: preliminary results of a prospective multicenter study","volume":"60","author":"Reddy","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.01.028_b0050","first-page":"298A","article-title":"High sustained virologic response rates in liver transplant recipients with recurrent HCV genotype 1 infection receiving ABT-450\/r\/ombitasvir+dasabuvir plus ribavirin","volume":"60","author":"Mantry","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.01.028_b0055","first-page":"201A","article-title":"Multicenter experience using sofosbuvir and simeprevir with\/without ribavirin to treat HCV genotype 1 after liver transplantation","volume":"60","author":"Pungpapong","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.01.028_b0060","first-page":"1267A","article-title":"All oral, fixed-dose combination therapy with Daclatasvir\/Asunaprevir\/Beclabuvir\u00b1Ribavirin for chronic genotype 1 infection and compensated cirrhosis: UNITY-2 phase 3 SVR12 results","volume":"60","author":"Muir","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.01.028_b0065","first-page":"1271A","article-title":"All oral, fixed-dose combination therapy with Daclatasvir\/Asunaprevir\/Beclabuvir for non-cirrhotic patients with chronic genotype 1 infection: UNITY-1 phase 3 SVR12 results","volume":"60","author":"Poordad","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.01.028_b0070","first-page":"318A","article-title":"Efficacy and safety of MK-5172 + MK-8742 \u00b1 ribavirin in HCV mono-infected and HIV\/HCV co-infected treatment-na\u00efve, non-cirrhotic patients with hepatitis C virus genotype 1 infection: the C-WORTHY study (Final results, Parts A and B)","volume":"60","author":"Sulkowski","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.01.028_b0075","first-page":"296A","article-title":"Efficacy and safety of MK-5172 and MK-8742 \u00b1 ribavirin in hepatitis C genotype 1 infected patients with cirrhosis or previous null response: final results of the C-WORTHY Study (Parts A and B)","volume":"60","author":"Lawitz","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.01.028_b0080","first-page":"1286A","article-title":"C-SWIFT: MK-5172+MK-8742+Sofosbuvir in treatment-naive patients with hepatitis C virus genotype 1 infection, with and without cirrhosis, for durations of 4, 6, or 8weeks","volume":"60","author":"Lawitz","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.01.028_b0085","first-page":"294A","article-title":"HBsAg loss with tenofovir disoproxil fumarate (TDF) plus peginterferon alfa-2a (PEG) in chronic hepatitis B (CHB): results of a global randomized controlled trial","volume":"60","author":"Marcellin","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.01.028_b0090","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/j.1478-3231.2012.02807.x","article-title":"Current limits and future challenges in the management of renal dysfunction in patients with cirrhosis: report from the International Club of Ascites","volume":"33","author":"Angeli","year":"2013","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2015.01.028_b0095","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1002\/lt.22433","article-title":"Hepatorenal syndrome, pharmacological therapy, and liver transplantation","volume":"17","author":"Gines","year":"2011","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2015.01.028_b0100","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1111\/j.1440-1746.2009.06132.x","article-title":"Terlipressin therapy for reversal of type 1 hepatorenal syndrome: a meta-analysis of randomized controlled trials","volume":"25","author":"Sagi","year":"2010","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2015.01.028_b0105","first-page":"255A","article-title":"Initial report of a large, randomized, double blind, placebo-controlled, phase 3 trial of terlipressin plus albumin for the treatment of type 1hepatorenal syndrome (HRS-1): the REVERSE study","volume":"60","author":"Boyer","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.01.028_b0110","first-page":"322A","article-title":"Reversal of hepatorenal syndrome type 1 (HRS-1) with terlipressin plus albumin versus placebo plus albumin \u2013 Not all responses are created equal \u2013 An analysis of the REVERSE and OT-0401 trials","volume":"60","author":"Sanyal","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.01.028_b0115","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1053\/j.gastro.2008.02.014","article-title":"A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome","volume":"134","author":"Sanyal","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2015.01.028_b0120","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1016\/S0168-8278(12)60003-8","article-title":"Management of critically-ill cirrhotic patients","volume":"56","author":"Gines","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.01.028_b0125","first-page":"254A","article-title":"A prospective open label randomized noninferiority trial to compare the efficacy and safety of monotherapy with noradrenaline and terlipressin in patients of cirrhosis with septic shock admitted to the Intensive care unit (NCT01836224)","volume":"60","author":"Choudhury","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.01.028_b0130","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1002\/hep.25532","article-title":"Prevalence and risk factors of infections by multiresistant bacteria in cirrhosis: a prospective study","volume":"55","author":"Fernandez","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.01.028_b0135","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1016\/j.cgh.2012.08.017","article-title":"High prevalence of antibiotic-resistant bacterial infections among patients with cirrhosis at a US liver center","volume":"10","author":"Tandon","year":"2012","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2015.01.028_b0140","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/j.jhep.2014.01.024","article-title":"Bacterial infections in cirrhosis: a position statement based on the EASL Special Conference 2013","volume":"60","author":"Jalan","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.01.028_b0145","first-page":"57AA","article-title":"The empirical antibiotic treatment of nosocomial spontaneous bacterial peritonitis in patients with decompensated liver cirrhosis: results of a randomized controlled clinical trial","volume":"60","author":"Piano","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.01.028_b0150","first-page":"279A","article-title":"A randomized trial of \u2018Imipenem versus Cefepime\u2019 in difficult to treat spontaneous bacterial peritonitis (SBP) and to evaluate the risk factors for treatment failure","volume":"60","author":"Jindal","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.01.028_b0155","first-page":"278A","article-title":"Efficacy and safety of a probiotic preparation in the secondary prophylaxis of hepatic encephalopathy in cirrhotic patients: final results of a double blind, randomized, placebo controlled study","volume":"60","author":"Dhiman","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.01.028_b0160","first-page":"376A","article-title":"The role of probiotics in the treatment of minimal hepatic encephalopathy. A prospective, randomized, placebo-controlled, double-blind study","volume":"60","author":"Vlachogiannakos","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.01.028_b0165","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1053\/jhep.2003.50133","article-title":"Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis","volume":"37","author":"Abraldes","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.01.028_b0170","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.jhep.2007.01.003","article-title":"Hepatology may have problems with putative surrogate outcome measures","volume":"46","author":"Gluud","year":"2007","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.01.028_b0175","first-page":"253A","article-title":"Lifestyle intervention by a 16-week programme of supervised diet and physical exercise ameliorates portal hypertension in patients with cirrhosis and obesity: the SportDiet study","volume":"60","author":"Berzigotti","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.01.028_b0180","doi-asserted-by":"crossref","first-page":"e1922","DOI":"10.1016\/j.cgh.2014.04.016","article-title":"Eight weeks of exercise training increases aerobic capacity and muscle mass and reduces fatigue in patients with cirrhosis","volume":"12","author":"Zenith","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2015.01.028_b0185","first-page":"246A","article-title":"Changes on hepatic venous pressure gradient induced by a physical exercise program in cirrhotic patients: a randomized open clinical trial","volume":"60","author":"Macias-Rodriguez","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.01.028_b0190","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.jhep.2010.04.008","article-title":"A position statement on NAFLD\/NASH based on the EASL 2009 special conference","volume":"53","author":"Ratziu","year":"2010","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.01.028_b0195","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1053\/j.gastro.2012.04.001","article-title":"The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology","volume":"142","author":"Chalansani","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2015.01.028_b0200","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/j.1440-1746.2008.05640.x","article-title":"Clinical features and outcomes of cirrhosis due to non-alcoholic steatohepatitis compared with cirrhosis caused by chronic hepatitis C","volume":"24","author":"Yatsuli","year":"2009","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2015.01.028_b0205","first-page":"226A","article-title":"The prognostic relevance of liver histology features in nonalcoholic fatty liver disease: the PRELHIN study","volume":"60","author":"Angulo","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.01.028_b0210","first-page":"225A","article-title":"Early phase 1 clinical trial results of GR-MD-02, a galectin-3 inhibitor, in patients having non-alcoholic steatohepatitis (NASH) with advanced fibrosis","volume":"60","author":"Harrison","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.01.028_b0215","first-page":"305A","article-title":"Effects of bariatric surgery on severe liver injury in morbid obese patients with proven NASH: a prospective study","volume":"60","author":"Lassailly","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.01.028_b0220","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/nrgastro.2011.134","article-title":"Alcoholic liver disease: pathogenesis and new targets for therapy","volume":"8","author":"Altamirano","year":"2011","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2015.01.028_b0225","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1053\/jhep.2000.8627","article-title":"Short- and long-term outcome of severe alcohol-induced hepatitis treated with steroids or enteral nutrition: a multicenter randomized trial","volume":"32","author":"Cabr\u00e9","year":"2000","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.01.028_b0230","first-page":"269A","article-title":"Impact of intensive enteral nutrition in association with corticosteroids in the treatment of severe alcoholic hepatitis: a multicenter randomized controlled trial","volume":"60","author":"Moreno","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.01.028_b0235","first-page":"1267A","article-title":"Steroids or pentoxifylline for alcoholic hepatitis: results of the STOPAH trial","volume":"60","author":"Thursz","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.01.028_b0240","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3322\/caac.20107","article-title":"Global cancer statistics","volume":"61","author":"Jemal","year":"2011","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.jhep.2015.01.028_b0245","first-page":"280A","article-title":"Real world risk score for hepatocellular carcinoma (RWS-HCC): development and external validation of a clinically practical score to identify low risk individuals","volume":"60","author":"Poh","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.01.028_b0250","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1056\/NEJMra1001683","article-title":"Hepatocellular carcinoma","volume":"365","author":"El-Serag","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2015.01.028_b0255","first-page":"281A","article-title":"Diabetes mellitus is associated with an increased risk of HCC in a large prospective cohort with long term follow-up","volume":"60","author":"King","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.01.028_b0260","first-page":"281A","article-title":"Hepatocellular carcinoma (HCC) surveillance among cirrhotic patients with commercial health insurance: national rates and determinants of surveillance","volume":"60","author":"Goldberg","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.01.028_b0265","first-page":"282A","article-title":"A multicenter randomized control trial of percutaneous cryoablation versus radiofrequency ablation therapy in patients with hepatocellular carcinoma","volume":"60","author":"Wang","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.01.028_b0270","first-page":"198A","article-title":"Antiplatelet therapy is associated with better prognosis in patients with hepatitis B virus-related hepatocellular carcinoma after resection surgery","volume":"60","author":"Su","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.01.028_b0275","first-page":"446A","article-title":"Short waiting time predicts early recurrence of hepatocellular carcinoma after liver transplantation: a multicenter study supporting the \u201cablate and wait\u201d principle","volume":"60","author":"Mehta","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.01.028_b0280","first-page":"253A","article-title":"Multicenter study of down-staging of hepatocellular carcinoma (HCC) to within Milan criteria before liver transplantation (LT)","volume":"60","author":"Mehta","year":"2014","journal-title":"Hepatology"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827815000598?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827815000598?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,25]],"date-time":"2018-09-25T22:21:06Z","timestamp":1537914066000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827815000598"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5]]},"references-count":56,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["S0168827815000598"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2015.01.028","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2015,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical trial watch: Reports from the AASLD Liver Meeting\u00ae, Boston, November 2014","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2015.01.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2015 European Association for the Study of the Liver. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}